EVALUATION IN YOUNG CHILDREN OF THE URABE AM 9 STRAIN OF LIVE ATTENUATED MUMPS VACCINE IN COMPARISON WITH THE JERYL LYNN STRAIN

Publisher Website
Google Scholar
Abstract
Urabe Am 9, a new strain of mumps vaccine, originally developed in Japan, was evaluated in children 14-20 mo. of age in a comparative trial with the Jeryl Lynn strain. Both vaccines performed well. The antibody responses were measured using a neutralization test and a hemolysis-in-gel test. The seroconversion rates at 6 wk, as detected with either one or both tests, were 55/58 (94.8%) after the Urabe Am 9 and 58/60 (96.7%) after the Jeryl Lynn vaccine. Only mild infrequent adverse reactions were observed. It is concluded that both strains of live attenuated mumps vaccine are immunogenic and well-tolerated in this age group.